Does Stelara Treat Ulcerative Colitis?
Yes, Stelara (ustekinumab) is FDA-approved for moderately to severely active ulcerative colitis (UC) in adults and children 6 years and older who have had an inadequate response to other treatments like TNF blockers.[1] It targets interleukins 12 and 23, reducing inflammation in the gut.
How Does Stelara Work for UC?
Stelara blocks proteins that drive immune overactivity in UC. Patients start with intravenous infusions at weeks 0, 8, and 16, then switch to subcutaneous injections every 8 weeks. Clinical trials showed 15-18% of patients achieved clinical remission at week 8 (vs. 5% on placebo), with sustained benefits up to a year.[2][1]
Who Qualifies for Stelara in UC?
It's for patients unresponsive to conventional therapies (e.g., steroids, immunomodulators) or biologics like Humira or Remicade. Not first-line; gastroenterologists assess based on disease severity via endoscopy and symptoms like frequent bloody stools or urgency.[3]
What Do Real-World Results Show?
In practice, about 40-50% of UC patients on Stelara reach steroid-free remission after a year, though response varies. It's effective for maintaining remission long-term, with lower rates of colectomy compared to TNF inhibitors.[4] Some lose response over time, needing dose adjustments.
Common Side Effects and Risks
Upper respiratory infections (10-20%), headache, and fatigue occur most often. Serious risks include infections (e.g., TB reactivation—screening required), malignancy, and rare gut perforations. No increased cancer risk in trials, but monitor long-term.[1][5] Avoid live vaccines.
How Does Stelara Compare to Other UC Drugs?
| Drug | Target | Remission Rate (Week 8) | Dosing | Key Edge |
|------|--------|--------------------------|--------|----------|
| Stelara | IL-12/23 | 15-18% | IV then subQ every 8 wks | Better for TNF failures; fewer injections |
| Entyvio (vedolizumab) | Gut integrin | 17% | IV every 8 wks | Gut-specific; lower systemic infection risk |
| Humira (adalimumab) | TNF | 10-15% | SubQ weekly/biweekly | First-line biologic; more flexible dosing |
| Xeljanz (tofacitinib) | JAK | 18% | Oral daily | Pill form; faster onset |
Stelara shines post-TNF failure but costs more upfront.[6]
Cost and Access Issues
A year's supply runs $50,000-$80,000 without insurance; patient assistance programs from Janssen cut copays to $5/month for eligible U.S. patients.[7] Biosimilars are in development but face patent hurdles until 2023-2030 variants expire—check DrugPatentWatch.com for updates.[8]
When Might Stelara Fail or Need Switching?
Primary non-response hits 20-30%; secondary loss in 10-20% yearly due to antibodies. Switch to JAK inhibitors or Entyvio if no improvement by week 16. Pregnancy data shows no major risks, but discuss with doctors.[9]
[1] FDA Label: https://www.accessdata.fda.gov/drugsatfdadocs/label/2023/761044s029lbl.pdf
[2] UNIFI Trial (NEJM 2020): https://www.nejm.org/doi/full/10.1056/NEJMoa1900750
[3] ACG Guidelines: https://journals.lww.com/ajg/fulltext/2020/10000/acgclinical_guideline__ulcerative_colitis_in.13.aspx
[4] Real-world study (Inflamm Bowel Dis 2022): https://academic.oup.com/ibdjournal/article/28/10/1525/6523456
[5] Stelara Safety Data: https://www.stelara.com/
[6] Comparative efficacy meta-analysis (Lancet 2021): https://www.thelancet.com/journals/langas/article/PIIS2468-1253(21)00045-7/fulltext
[7] Janssen CarePath: https://www.janssencarepath.com/hcp/stelara/uc
[8] DrugPatentWatch: https://www.drugpatentwatch.com/p/tradename/STELARA
[9] Pregnancy registry (J Crohns Colitis 2023): https://academic.oup.com/ecco-jcc/article/17/1/1/6745123